Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset
Moderna closed at $23.72 on Friday, near its 52-week low and down 38% over the past year. The company is now the most shorted stock in the S&P 500, with short interest near 18% as COVID vaccine sales collapse. Moderna has announced a new three-year strategy, $1.5 billion in new debt, and pipeline cuts while focusing on mRNA drugs for cancer and respiratory disease.